Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +336.76%
#4 aPriori aPriori +108.27%
#5 Bedrock Bedrock +74.39%
#6 Cysic Cysic +49.09%
#7 Prom Prom +38.71%
#8 Playnance Playnance +35.10%
#9 COTI COTI +26.15%
#10 Nillion Nillion +24.13%
Coin of the day
Wrapped One Wrapped One
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Rosetta Genomics Ltd. Rosetta Genomics Ltd.

Rosetta Genomics Ltd.

ROSGQ
Classifica tra le azioni #42629
Rosetta Genomics Ltd. is a global entity specializing in genomic diagnostics.... Rosetta Genomics Ltd. is a global entity specializing in genomic diagnostics. The company leverages its proprietary microRNA technologies to offer a range of diagnostic assays, including RosettaGX Cancer Origin, which helps pinpoint the primary source of metastatic cancer; mi-KIDNEY, designed for classifying kidney tumors from pathological specimens; RosettaGX Reveal, used to interpret indeterminate thyroid fine-needle aspirate results; and various mi-LUNG diagnostic tests. In addition to its microRNA-based portfolio, Rosetta Genomics provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay. This assay serves as an adjunct to, rather than a substitute for, conventional diagnostic methods, aiding in the initial detection of bladder carcinoma in patients with hematuria and in the ongoing surveillance for tumor recurrence in those previously diagnosed with bladder cancer. The company also offers ERG/PTEN, which are FISH-based tests providing prognostic information for prostate cancer. Furthermore, Rosetta Genomics supplies ALK/ROS1, a set of FISH-based predictive tests specifically intended for individuals with late-stage lung cancer, along with PCR gene mutation analysis for patients with bladder, lung, colon, and melanoma cancers. Its diagnostic solutions are utilized by a diverse group of medical professionals, including oncologists, urologists, endocrinologists, and cytopathologists, empowering them to deliver improved patient care. The company holds a licensing agreement with Max Planck Innovation GmbH, securing rights to its patented microRNA technologies for both diagnostic applications and research initiatives. Moreover, Rosetta Genomics has entered into a collaborative partnership with Meir Medical Center to develop a microRNA classifier, focusing on non-small cell lung cancer patients being considered for immuno-oncology therapies. Established in 2000, Rosetta Genomics Ltd. maintains its headquarters in Rehovot, Israel.
Prezzo delle azioni
$0.0001
Ultima sincronizzazione: 2026-08-11
Capitalizzazione di mercato
$593.00
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
IL
Scambia Rosetta Genomics Ltd. (ROSGQ)

Categoria

Healthcare
Rapporto P/S per Rosetta Genomics Ltd. (ROSGQ)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Rosetta Genomics Ltd., il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per Rosetta Genomics Ltd. da 2026 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
Non abbastanza dati per le date fornite.
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
4.61 -
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
5.46 -
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
- -
CN
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
9.92 -
US
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
15.33 -
US